Moleculin Biotech, Inc.

NasdaqCM:MBRX Stock Report

Market Cap: US$7.0m

Moleculin Biotech Future Growth

Future criteria checks 0/6

Moleculin Biotech is forecast to grow earnings and revenue by 37.4% and 82.3% per annum respectively while EPS is expected to grow by 47.5% per annum.

Key information

37.4%

Earnings growth rate

47.5%

EPS growth rate

Biotechs earnings growth27.3%
Revenue growth rate82.3%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Aug 2024

Recent future growth updates

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01
Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11
Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Mar 28
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 11
We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Aug 18
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Moleculin Biotech to join Russell 2000 Index

Jun 15

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?

May 04
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?

Moleculin shares soar after promising Annamycin pre-clinical readout

Feb 02

Moleculin Biotech under pressure on reverse stock split

Jan 29

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jan 15
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas

Dec 29

Earnings and Revenue Growth Forecasts

NasdaqCM:MBRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-31N/AN/A2
12/31/2025N/A-29N/AN/A2
12/31/2024N/A-22N/AN/A2
6/30/2024N/A-25-26-26N/A
3/31/2024N/A-27-25-25N/A
12/31/2023N/A-30-24-24N/A
9/30/2023N/A-26-26-26N/A
6/30/2023N/A-29-26-26N/A
3/31/2023N/A-30-29-29N/A
12/31/2022N/A-29-28-28N/A
9/30/2022N/A-25-25-25N/A
6/30/2022N/A-21-21-21N/A
3/31/2022N/A-18-20-20N/A
12/31/2021N/A-16-19-19N/A
9/30/2021N/A-16-18-18N/A
6/30/2021N/A-15-19-19N/A
3/31/2021N/A-21-17-17N/A
12/31/2020N/A-17-18-18N/A
9/30/2020N/A-19-20-19N/A
6/30/2020N/A-19-17-17N/A
3/31/2020N/A-10-18-18N/A
12/31/2019N/A-13-17-17N/A
9/30/2019N/A-12-16-16N/A
6/30/2019N/A-10-16-15N/A
3/31/2019N/A-14-14-13N/A
12/31/2018N/A-12-13-12N/A
9/30/2018N/A-12-12-11N/A
6/30/2018N/A-13-10-10N/A
3/31/2018N/A-11N/A-9N/A
12/31/2017N/A-10N/A-7N/A
9/30/2017N/A-8N/A-6N/A
6/30/2017N/A-7N/A-5N/A
3/31/2017N/A-4N/A-5N/A
12/31/2016N/A-4N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MBRX is forecast to have no revenue next year.

High Growth Revenue: MBRX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MBRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies